Checkmate pharmaceuticals skin#
Checkmate pharmaceuticals Activator#
Checkmate pharmaceuticals full#

Checkmate pharmaceuticals full#

It is our hope that Regeneron’s resources and expertise will help accelerate the development of vidutolimod and realization of the full potential of our virus-like particle (VLP) platform for immunotherapy,” said Art Krieg, M.D., Checkmate’s Founder and Chief Scientific Officer.

Checkmate pharmaceuticals Activator#

“We believe that the data we have generated with vidutolimod positions Checkmate at the forefront of the innate immune activator field. “We are thrilled that Checkmate will become part of Regeneron, a biotechnology leader that shares our deep appreciation for science, hunger for ground-breaking discoveries and commitment to helping patients defeat cancer,” said Alan Bash, President and Chief Executive Officer of Checkmate. We look forward to welcoming the Checkmate team and their complementary scientific acumen to the Regeneron family.” “The unique combination of a differentiated Toll-like receptor 9 with other antibody-based oncology agents may result in increased clinical benefit and provide new treatment options for patients in need. Schleifer, M.D., Ph.D., President and Chief Executive Officer of Regeneron. “As we continue to advance and expand our research efforts in immuno-oncology, the acquisition of Checkmate will add a promising new modality to Regeneron’s toolkit of potential approaches for difficult-to-treat cancers,” said Leonard S. The proposed acquisition values Checkmate at a total equity value of approximately $250 million.Ĭheckmate’s lead investigational candidate is vidutolimod, an advanced generation CpG-A oligodeoxynucleotide Toll-like receptor 9 (TLR9) agonist delivered in a virus-like particle. (NASDAQ: CMPI) a clinical stage biopharmaceutical company focused on proprietary technology to harness the power of the immune system to combat cancer, today announced a definitive agreement for the acquisition of Checkmate by Regeneron at an all-cash price of $10.50 per share of Checkmate common stock. (NASDAQ: REGN) and Checkmate Pharmaceuticals, Inc. and CAMBRIDGE, Mass., Ap(GLOBE NEWSWIRE) - Regeneron Pharmaceuticals, Inc.

Checkmate pharmaceuticals skin#

Vidutolimod is currently being studied in combination with other agents for melanoma, non-melanoma skin cancers, and head and neck cancer Lead investigational asset vidutolimod is a potential best-in-class TLR9 agonist, with demonstrated clinical responses observed in PD-1 refractory melanoma as monotherapy If you or someone you know would like to learn about our ongoing clinical trials, click here.Proposed ~$250 million all-cash acquisition strengthens Regeneron’s portfolio of diverse and combinable immuno-oncology candidates The Checkmate Pharmaceuticals team is committed to improving clinical outcomes for these patients. We believe patients with the most difficult-to-treat cancers should have effective treatment options. Our science is directed toward helping patients for whom other therapies have not worked or are unlikely to work. OUR MISSION: Leverage our leadership in innate immunity to develop and deliver therapies that enable patients to defeat cancer. OUR VISION: A world in which immunity defeats cancer. Our future is bright, as we continue to work on innovative ways to improve patient response rates by activating innate immunity in combination with other new immunotherapies for many types of cancer. The combination of vidutolimod with a checkpoint inhibitor, which blocks proteins that stop the immune system from attacking cancer cells, may improve clinical responses for patients. Our leading clinical candidate vidutolimod is a non-infectious, biologic virus-like particle (VLP) containing CpG-A DNA, which stimulates Toll-like receptor 9 (TLR9) and is intended to drive a stronger killer T cell response to tumors. We’re on the path to improving patients’ response to immunotherapy. He continues to lead our search for innovative ways to maximize the effectiveness of the body’s immune response to tumors. This ground-breaking discovery provided the foundation for the exciting science we are doing today. In 1994 our founder, Art Krieg, and his colleagues discovered unmethylated CpG in bacterial DNA as an immune activator. At Checkmate, this life-saving journey has become our mission. As immunotherapy evolved, the scientific quest remained the same: to empower humans’ immunity to defeat cancer.